Development and optimization of curcumin analog nano-bilosomes using 21.31full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay / Haidy Abbas, Yasmin A. El-Feky, Majid Mohammad Al-Sawahli, Nehal M. EL-Deeb, Hala Bakr El-Nassan, Mariam Zewail
Abstract Curcumin (CU) is a natural polyphenolic phytoingredient. CU has anti-inflammatory, anti-oxidant, and anticancer activities. The poor solubility, bioavailability, and stability of CU diminish its clinical application. Hence, structural modification of CU is highly recommended. The CU analog; 3,5-bis(4-bromobenzylidene)-1-propanoylpiperidin-4-one (PIP) exhibited high stability, safety, and more potent antiproliferative activity against hepatocellular carcinoma. In the present study, nano-bilosomes (BLs) were formulated to augment PIP delivery and enhance its solubility. A 2 1 .3 1 full factorial design was adopted to prepare the synthesized PIP-loaded BLs. Optimized F4 showed a biphasic release pattern extended over 24 h, with EE%, ZP, and PS of 90.21 ± 1.0%, −27.05 ± 1.08 mV, and 111.68 ± 1.4 nm. PIP-loaded BLs were tested for safety against a non-cancerous cell line (Wi-38) and for anticancer activity against the Huh-7 human hepatocellular carcinoma cells and compared to the standard anticancer drug doxorubicin (Dox). The anticancer selectivity index of PIP-loaded BLs recorded 420.55 against Huh-7 liver cancer cells, markedly higher than a CU suspension (18.959) or the Dox (20.82). The antiproliferative activity of nano-encapsulated PIP was roughly equivalent to Dox. PIP-loaded BLs, showed enhanced drug solubility, and enhanced anticancer effect, with lower toxicity and higher selectivity against Huh-7 liver cancer cells, compared to the parent CU.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Drug delivery - 29(2022), 1, Seite 714-727 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abbas, Haidy [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
3,5-bis(4-bromobenzylidene)-1-propanoylpiperidin-4-one |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| doi: |
10.1080/10717544.2022.2044938 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011124172 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011124172 | ||
| 003 | DE-627 | ||
| 005 | 20230713210817.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10717544.2022.2044938 |2 doi | |
| 035 | |a (DE-627)KFL011124172 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/10717544.2022.2044938 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Abbas, Haidy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and optimization of curcumin analog nano-bilosomes using 21.31full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma:in-vitroevaluation,in-vivosafety assay |c Haidy Abbas, Yasmin A. El-Feky, Majid Mohammad Al-Sawahli, Nehal M. EL-Deeb, Hala Bakr El-Nassan, Mariam Zewail |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Curcumin (CU) is a natural polyphenolic phytoingredient. CU has anti-inflammatory, anti-oxidant, and anticancer activities. The poor solubility, bioavailability, and stability of CU diminish its clinical application. Hence, structural modification of CU is highly recommended. The CU analog; 3,5-bis(4-bromobenzylidene)-1-propanoylpiperidin-4-one (PIP) exhibited high stability, safety, and more potent antiproliferative activity against hepatocellular carcinoma. In the present study, nano-bilosomes (BLs) were formulated to augment PIP delivery and enhance its solubility. A 2 1 .3 1 full factorial design was adopted to prepare the synthesized PIP-loaded BLs. Optimized F4 showed a biphasic release pattern extended over 24 h, with EE%, ZP, and PS of 90.21 ± 1.0%, −27.05 ± 1.08 mV, and 111.68 ± 1.4 nm. PIP-loaded BLs were tested for safety against a non-cancerous cell line (Wi-38) and for anticancer activity against the Huh-7 human hepatocellular carcinoma cells and compared to the standard anticancer drug doxorubicin (Dox). The anticancer selectivity index of PIP-loaded BLs recorded 420.55 against Huh-7 liver cancer cells, markedly higher than a CU suspension (18.959) or the Dox (20.82). The antiproliferative activity of nano-encapsulated PIP was roughly equivalent to Dox. PIP-loaded BLs, showed enhanced drug solubility, and enhanced anticancer effect, with lower toxicity and higher selectivity against Huh-7 liver cancer cells, compared to the parent CU | ||
| 653 | |a Curcumin | ||
| 653 | |a 3,5-bis(4-bromobenzylidene)-1-propanoylpiperidin-4-one | ||
| 653 | |a hepatocellular carcinoma | ||
| 653 | |a nano-bilosomes | ||
| 653 | |a bile salts | ||
| 700 | 1 | |a El-Feky, Yasmin A. |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Sawahli, Majid Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a EL-Deeb, Nehal M. |e verfasserin |4 aut | |
| 700 | 1 | |a El-Nassan, Hala Bakr |e verfasserin |4 aut | |
| 700 | 1 | |a Zewail, Mariam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug delivery |d Abingdon : Taylor & Francis Group, 1993 |g 29(2022), 1, Seite 714-727 |h Online-Ressource |w (DE-627)KFL000005983 |w (DE-600)2020593-4 |w (DE-576)273878719 |x 1521-0464 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:1 |g pages:714-727 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/10717544.2022.2044938 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_05 | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 1 |h 714-727 | ||